Effectiveness of Khat on Eyelid Wound Healing After Oculoplastic Surgery - a Prospective Study.
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03917641 |
Recruitment Status :
Not yet recruiting
First Posted : April 17, 2019
Last Update Posted : April 17, 2019
|
Sponsor:
Sheba Medical Center
Information provided by (Responsible Party):
Sheba Medical Center
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | April 1, 2019 | ||||
First Posted Date ICMJE | April 17, 2019 | ||||
Last Update Posted Date | April 17, 2019 | ||||
Estimated Study Start Date ICMJE | July 1, 2019 | ||||
Estimated Primary Completion Date | July 1, 2020 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
|
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | No Changes Posted | ||||
Current Secondary Outcome Measures ICMJE | Not Provided | ||||
Original Secondary Outcome Measures ICMJE | Not Provided | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | Effectiveness of Khat on Eyelid Wound Healing After Oculoplastic Surgery - a Prospective Study. | ||||
Official Title ICMJE | Effectiveness of Khat on Eyelid Wound Healing After Oculoplastic Surgery - a Prospective Study. | ||||
Brief Summary | The post operative routine after Oculoplastic Surgery includes usage of cold compressions for symptomatic relief and decreasing of the edema and local hematomas in the first few days after the surgery. Khat (Catha edulis) is a plant that is used mainly for chewing and has a known stimulating effect, some patients report major improvement after including these leaves in the compressions they use after surgery. Khat contains the chemical ingredients Cathine and Cathinone, which are amphetamine-like alkaloids and probably the main contributors for its active effects. Our main goal is to use compressions that include the Khat leaves and check their effect on reducing the edema and hematomas after oculoplastic surgery. | ||||
Detailed Description | Not Provided | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Not Applicable | ||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Intervention Model Description: Each participant is his own control Masking: None (Open Label)Primary Purpose: Treatment |
||||
Condition ICMJE |
|
||||
Intervention ICMJE | Biological: Khat leaves
One of the two compressions (one per each eye) the patient will use will contain the Khat leaves.
|
||||
Study Arms ICMJE | Experimental: Patients after Oculoplastic surgery
Each participant will use one compression with Khat leaves and another standard compression and will decide on which eye to use which compression. The compressions will be used for 10 minutes per every waking hour in the first 2 days post-op. The patient will take pictures of both his eyes in days 1,3 and 7 post operative days. Intervention: Biological: Khat leaves
|
||||
Publications * | Malhotra R, Ziahosseini K, Poitelea C, Litwin A, Sagili S. Effect of Manuka Honey on Eyelid Wound Healing: A Randomized Controlled Trial. Ophthalmic Plast Reconstr Surg. 2017 Jul/Aug;33(4):268-272. doi: 10.1097/IOP.0000000000000743. | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Not yet recruiting | ||||
Estimated Enrollment ICMJE |
10 | ||||
Original Estimated Enrollment ICMJE | Same as current | ||||
Estimated Study Completion Date ICMJE | July 1, 2021 | ||||
Estimated Primary Completion Date | July 1, 2020 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | Yes | ||||
Contacts ICMJE |
|
||||
Listed Location Countries ICMJE | Israel | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03917641 | ||||
Other Study ID Numbers ICMJE | SHEBA-17-4804-GBS-CTIL | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE |
|
||||
Responsible Party | Sheba Medical Center | ||||
Study Sponsor ICMJE | Sheba Medical Center | ||||
Collaborators ICMJE | Not Provided | ||||
Investigators ICMJE | Not Provided | ||||
PRS Account | Sheba Medical Center | ||||
Verification Date | April 2019 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |